T 2562/18 vom 21.07.2020
- Europäischer Rechtsprechungsidentifikator
- ECLI:EP:BA:2020:T256218.20200721
- Datum der Entscheidung
- 21. Juli 2020
- Aktenzeichen
- T 2562/18
- Antrag auf Überprüfung von
- -
- Anmeldenummer
- 11153847.6
- IPC-Klasse
- A61M 1/36
- Verfahrenssprache
- Englisch
- Verteilung
- Nicht verteilt (D)
- Download
- Entscheidung auf Englisch
- Amtsblattfassungen
- Keine AB-Links gefunden
- Weitere Entscheidungen für diese Akte
- -
- Zusammenfassungen für diese Entscheidung
- -
- Bezeichnung der Anmeldung
- Citrate anticoagulation system for extracorporeal blood treatments
- Name des Antragstellers
- Nikkiso Co., Ltd.
- Name des Einsprechenden
- B. Braun Avitum AG
Fresenius Medical Care AG & Co. KGaA - Kammer
- 3.2.02
- Leitsatz
- -
- Relevante Rechtsnormen
- European Patent Convention Art 100(b) (2007)European Patent Convention Art 123(2) (2007)European Patent Convention Art 54(1) (2007)European Patent Convention Art 54(2) (2007)European Patent Convention Art 56 (2007)European Patent Convention Art 76(1) (2007)European Patent Convention Art 84 (2007)
- Schlagwörter
- Grounds for opposition - insufficiency of disclosure (no)
Novelty - main request (no)
Novelty - auxiliary request 2 (yes)
Claims - clarity
Claims - auxiliary requests 1 and 2 (yes)
Amendments - extension beyond the content of the original
application and the parent application as filed - auxiliary
request 1 (yes) - auxiliary request 2 (no)
Inventive step - auxiliary request 2 (yes) - Orientierungssatz
- -
- Zitierte Akten
- T 0404/16
- Zitierende Akten
- T 0404/16
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The case is remitted to the Opposition Division with the order to maintain the patent as amended in the following version:
- claims: 1-9 according to auxiliary request 2 filed with letter dated 16 May 2019;
- description: pages 2, 4-7, 9 of the patent specification, and pages 3 and 8 filed during the oral proceedings before the Opposition Division on 2 July 2018;
- drawings: Figures 1-6 of the patent specification.